JNK Pathway: Pathway Poster Library

Download a pathway poster for your lab.

All the posters in the Proteintech library are available in PDF format or can be requested as a hard copy.


JNK Signaling

JNKs (c-Jun N-terminal kinases), also known as stress-activated protein kinases, are a subfamily of mitogen-activated protein (MAP) kinases. They are strongly stimulated by numerous environmental stresses but also by mitogens, inflammatory cytokines, oncogenes, and inducers of cell differentiation or morphogenesis (1).

Three major genes have been identified as regulators of the JNK pathway. JNK1 and JNK2 have broad tissue distribution and play a significant role in insulin resistance, inflammation, and cell signaling. JNK3 is predominantly found in the central nervous system (CNS) neurons. The JNKs are activated by phosphorylation on threonine and tyrosine residues via MKK4 and MKK7; inactivation of the JNKs is induced by MAPK phosphatases, which usually function in a negative feedback loop (2).

Since deregulation of JNK is linked with various diseases, including neurodegenerative disorders (Parkinson’s, Alzheimer’s), diabetes, cancer, cardiac hypertrophy, and asthma, JNK inhibitors, activators, and isoforms have a potential as therapeutic targets. (3)

Download the JNK Pathway poster here

Related Antibodies

ASK1 HSP70 MEK4 PI3K P55(Gamma)
ATF2-Specific IRS1 MEKK3 Rac1
CDC42 JIP1 MKK7 RRAS
CRK JNK MKP-2 SOS1
DLK1 JNK2 MLK3 TAK1
ELK1 MAPK10 NFATC3 TAU
ERK1/2 MEK1-Specific P53 TRADD
GRB2 MEK2 pan Ras TRAF6
Browse more pathway posters here

Request a printed poster



Tick the box below if you would like to receive email updates from Proteintech® including antibody news, exclusive discounts, upcoming events and blog articles. You can unsubscribe at any time.


 

  1. c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges.
  2. The role of scaffold proteins in JNK signalling.
  3. JNK pathway signaling: a novel and smarter therapeutic targets for various biological diseases.
Blog

Posted:
20 June, 2017

Share:


Back
to top